Literature DB >> 28390905

Membrane-type matrix metalloproteases as diverse effectors of cancer progression.

S Pauliina Turunen1, Olga Tatti-Bugaeva2, Kaisa Lehti3.   

Abstract

Membrane-type matrix metalloproteases (MT-MMP) are pivotal regulators of cell invasion, growth and survival. Tethered to the cell membranes by a transmembrane domain or GPI-anchor, the six MT-MMPs can exert these functions via cell surface-associated extracellular matrix degradation or proteolytic protein processing, including shedding or release of signaling receptors, adhesion molecules, growth factors and other pericellular proteins. By interactions with signaling scaffold or cytoskeleton, the C-terminal cytoplasmic tail of the transmembrane MT-MMPs further extends their functionality to signaling or structural relay. MT-MMPs are differentially expressed in cancer. The most extensively studied MMP14/MT1-MMP is induced in various cancers along malignant transformation via pathways activated by mutations in tumor suppressors or proto-oncogenes and changes in tumor microenvironment including cellular heterogeneity, extracellular matrix composition, tissue oxygenation, and inflammation. Classically such induction involves transcriptional programs related to epithelial-to-mesenchymal transition. Besides inhibition by endogenous tissue inhibitors, MT-MMP activities are spatially and timely regulated at multiple levels by microtubular vesicular trafficking, dimerization/oligomerization, other interactions and localization in the actin-based invadosomes, in both tumor and the stroma. The functions of MT-MMPs are multifaceted within reciprocal cellular responses in the evolving tumor microenvironment, which poses the importance of these proteases beyond the central function as matrix scissors, and necessitates us to rethink MT-MMPs as dynamic signaling proteases of cancer. This article is part of a Special Issue entitled: Matrix Metalloproteinases edited by Rafael Fridman.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  EMT; Membrane-type matrix metalloprotease; cancer invasion; extracellular matrix; proteolysis; tumor microenvironment

Mesh:

Substances:

Year:  2017        PMID: 28390905     DOI: 10.1016/j.bbamcr.2017.04.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Cell Res        ISSN: 0167-4889            Impact factor:   4.739


  39 in total

1.  MT1-MMP Binds Membranes by Opposite Tips of Its β Propeller to Position It for Pericellular Proteolysis.

Authors:  Tara C Marcink; Jayce A Simoncic; Bo An; Anna M Knapinska; Yan G Fulcher; Narahari Akkaladevi; Gregg B Fields; Steven R Van Doren
Journal:  Structure       Date:  2018-11-21       Impact factor: 5.006

2.  MMP14 is required for delamination of chick neural crest cells independently of its catalytic activity.

Authors:  Cyril Andrieu; Audrey Montigny; Anne Bibonne; Evangeline Despin-Guitard; Dominique Alfandari; Eric Théveneau
Journal:  Development       Date:  2020-04-12       Impact factor: 6.868

3.  Translocating a High-Affinity Designer TIMP-1 to the Cell Membrane for Total Renal Carcinoma Inhibition: Putting the Prion Protein to Good Use.

Authors:  Bingjie Jiang; Yuewei Xu; Yihe Zhang; Meng Huee Lee
Journal:  Mol Cell Biol       Date:  2019-08-27       Impact factor: 4.272

4.  Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma.

Authors:  Charles Marusak; Varsha Thakur; Yuan Li; Juliano T Freitas; Patrick M Zmina; Vijay S Thakur; Mayland Chang; Ming Gao; Jiufeng Tan; Min Xiao; Yiling Lu; Gordon B Mills; Keith Flaherty; Dennie T Frederick; Benchun Miao; Ryan J Sullivan; Tabea Moll; Genevieve M Boland; Meenhard Herlyn; Gao Zhang; Barbara Bedogni
Journal:  Clin Cancer Res       Date:  2020-08-20       Impact factor: 12.531

Review 5.  Glioma Stem Cell Niches in Human Glioblastoma Are Periarteriolar.

Authors:  Vashendriya V V Hira; Diana A Aderetti; Cornelis J F van Noorden
Journal:  J Histochem Cytochem       Date:  2018-01-12       Impact factor: 2.479

6.  Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity.

Authors:  Jingya Guo; Yong Liang; Diyuan Xue; Jiao Shen; Yueqi Cai; Jiankun Zhu; Yang-Xin Fu; Hua Peng
Journal:  Cell Res       Date:  2021-08-10       Impact factor: 25.617

7.  A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors.

Authors:  Diyuan Xue; Benjamin Moon; Jing Liao; Jingya Guo; Zhuangzhi Zou; Yanfei Han; Shuaishuai Cao; Yang Wang; Yang-Xin Fu; Hua Peng
Journal:  Sci Immunol       Date:  2022-01-07

8.  Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice.

Authors:  Simone Ragusa; Borja Prat-Luri; Alejandra González-Loyola; Sina Nassiri; Mario Leonardo Squadrito; Alan Guichard; Sabrina Cavin; Nikolce Gjorevski; David Barras; Giancarlo Marra; Matthias P Lutolf; Jean Perentes; Emily Corse; Roberta Bianchi; Laureline Wetterwald; Jaeryung Kim; Guillermo Oliver; Mauro Delorenzi; Michele De Palma; Tatiana V Petrova
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

Review 9.  Proteases Regulate Cancer Stem Cell Properties and Remodel Their Microenvironment.

Authors:  Anamarija Habič; Metka Novak; Bernarda Majc; Tamara Lah Turnšek; Barbara Breznik
Journal:  J Histochem Cytochem       Date:  2021-07-26       Impact factor: 2.479

10.  Progesterone and calcitriol reduce invasive potential of endometrial cancer cells by targeting ARF6, NEDD9 and MT1-MMP.

Authors:  Sana Waheed; Batsukh Dorjbal; Chad A Hamilton; G Larry Maxwell; Gustavo C Rodriguez; Viqar Syed
Journal:  Oncotarget       Date:  2017-11-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.